Chronic Myeloid Leukemia
Chronic Myeloid Leukemia
The latest news, research, and perspectives in chronic myeloid leukemia (CML). CML is caused by the BCR-ABL1 fusion gene, which is formed by a translocation between chromosomes 9 and 22 (the Philadelphia chromosome), that produces abnormal proteins leading to the development of leukemic cells.
Advertisement
Andrew MorenoChronic Myeloid Leukemia | November 13, 2024
Adverse events were common in patients with CML receiving first- or second-generation tyrosine kinase inhibitors.
Read More
Melissa BadamoChronic Myeloid Leukemia | October 30, 2024
The approval is based on results of the ASC4FIRST trial, which compared asciminib versus investigator-selected TKIs.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Ponatinib demonstrated long-term efficacy and manageable safety in patients with highly resistant, chronic phase CML.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Achieving deep molecular response has allowed for treatment discontinuation, making TFR a main goal of therapy.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Olverembatinib was well tolerated and showed strong antileukemic activity in patients with chronic phase CML.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Asciminib continues to demonstrate favorable safety and tolerability compared to TKIs in patients with chronic phase CML.
Advertisement
Rebecca AraujoChronic Myeloid Leukemia | September 23, 2024
Age ≥65 years, arrhythmia, and cardiogenic shock were associated with a significantly higher rate of acute heart failure.
Jorge Cortes, MDChronic Myeloid Leukemia | June 14, 2024
The rate of response was “significantly higher” with asciminib compared with tyrosine kinase inhibitors.
Sangeetha Venugopal, MDChronic Myeloid Leukemia | June 7, 2024
Sangeetha Venugopal, MD, engages outstanding issues in chronic myeloid leukemia treatment research.
Elias Jabbour, MDPrint | May 22, 2024
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Melissa BadamoPrint | April 30, 2024
Palliative care facilitates communication and helps with symptom management, the researchers noted.
Gwen Nichols, MDAcute Myeloid Leukemia | March 5, 2024
The goal of PedAL is to establish a data-driven developmental therapeutics program.
Katie KoskoChronic Myeloid Leukemia | March 5, 2024
The trial's treatment regimen included single-agent dasatinib for the first three months, followed by venetoclax.
Melissa BadamoAcute Lymphoblastic Leukemia | December 4, 2023
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
Guido Marcucci, MDChronic Myeloid Leukemia | November 29, 2023
Mice with CML who were given a synthetic version of miR-142 lived much longer and were even cured.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | November 2, 2023
Dr. Cortes chats about the “boom” in treatments for chronic myeloid leukemia (CML), and where he sees a need for balance.
Cecilia BrownChronic Myeloid Leukemia | October 11, 2023
Dr. Radich reflects on lessons in cowboy medicine, the genetics of luck, and a serendipitous meeting.
Cecilia BrownChronic Myeloid Leukemia | February 8, 2024
The FDA also announced it approved a new capsule dosage form of bosutinib.
Jorge Cortes, MDVideo Insights | September 14, 2023
Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO.
Cecilia BrownChronic Myeloid Leukemia | August 3, 2023
Researchers reviewed data from 107 patients with CML who developed a T315I mutation in BCR-ABL1.
Advertisement
Advertisement
Editorial Board